Neurocrine Biosciences Inc (NAS:NBIX)
$ 142 3.52 (2.54%) Market Cap: 14.29 Bil Enterprise Value: 13.24 Bil PE Ratio: 39.12 PB Ratio: 5.99 GF Score: 89/100

Neurocrine Biosciences Inc at Cowen HealthCare Conference Transcript

Mar 03, 2020 / 05:00PM GMT
Release Date Price: $92.57 (-3.88%)
Philip M. Nadeau
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

All right. Well, welcome once again to Cowen and Company's 40th Annual Health Care Conference. I'm Phil Nadeau, one of the biotech analysts here at Cowen, and it's my pleasure to conduct a fireside chat with Neurocrine Biosciences. These are truly exciting times for Neurocrine as INGREZZA is launching and doing quite well.

So we're happy to have with us Kevin Gorman, CEO; Kyle Gano, Chief Business Development and Strategy Officer, and Todd Tushla from IR. Guys, thanks for joining us.

Questions & Answers

Philip M. Nadeau
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Maybe, Kevin, we'll start with you. Could you give us a brief state of the company overview, what are the biggest strengths, biggest challenges? And what needs to happen to continue to drive outperformance over the next year or 2?

Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director

Sure, Phil.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot